@article{cb7bb3f149a74337b3f378cea0928e7b,
title = "Trans-synaptic degeneration as a mechanism of neurodegeneration in multiple sclerosis",
author = "Murphy, {Olwen C.} and Calabresi, {Peter A.} and Shiv Saidha",
note = "Funding Information: SS has received consulting fees from Medical Logix for the development of CME programs in neurology and has served on scientific advisory boards for Biogen, Novartis, Genentech Corporation, TG therapeutics & Bristol Myers Squibb. He has performed consulting for Novartis, Genentech Corporation, JuneBrain LLC, and Lapix therapeutics. He is the Principal Investigator of investigator-initiated studies funded by Genentech Corporation and Biogen. He previously received support from the Race to Erase MS foundation. He has received equity compensation for consulting from JuneBrain LLC and Lapix therapeutics. He was also the site investigator of trials sponsored by MedDay Pharmaceuticals, Clene Pharmaceuticals, and is the site investigator of a trial sponsored by Novartis. Funding Information: OCM receives funding from the Race to Erase MS Foundation. Funding Information: This work was funded by the National MS Society (RG-1606-08768 & RG-1907-34405 to SS), Race to Erase MS (to SS), and NIH/NINDS (R01NS082347 to PAC). ",
year = "2023",
month = dec,
doi = "10.4103/1673-5374.373661",
language = "English (US)",
volume = "18",
pages = "2682--2684",
journal = "Neural Regeneration Research",
issn = "1673-5374",
publisher = "Wolters Kluwer Medknow Publications",
number = "12",
}